KTPasithea Therapeutics Corp. KTTA · NASDAQ
$0.43 +4.80% (+$0.02)
- Market cap
- $13.7M
- Enterprise value
- -$45.7B
- P/E
- -
- Forward P/E
- -
- PEG
- -
- P/S
- -
- P/FCF
- -
- EV/EBITDA
- -
- ROIC
- -0.0%
- Gross margin
- -
- Net margin
- -
- Dividend yield
- -
- Payout ratio
- -
- Net debt/EBITDA
- -
- Beta
- 0.29
- Free float
- 96.4%
About the company
Pasithea Therapeutics Corp. (KTTA) is an American biotechnology company focused on the development and commercialization of new treatments for neurological and psychiatric disorders. With an emphasis on innovative approaches to treating depression, anxiety, and other mental health conditions, Pasithea is a leading player in the field of neuroscience research. The company is known for its strong focus on the research and development of new therapeutic solutions that can improve patients' quality of life. Pasithea Therapeutics also collaborates with academic and scientific institutions to accelerate innovation in its field. Pasithea Therapeutics Corp. (KTTA) shares could be suitable for investors looking to invest in biotechnology and healthcare with the potential for breakthrough discoveries in mental health treatment.
Sector
Healthcare
Industry
Biotechnology
CEO
Tiago Reis Marques
Employees
5
Headquarters
Miami Beach
Valuation
Is today's price reasonable?
Growth and estimates
Is it growing, and what comes next?
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
Financial health
Can it carry its debt?
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number